Cymed Ostomy

Cymed Ostomy

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cymed Ostomy, founded in 2003 and headquartered in Portland, USA, is a private commercial-stage company in the medical device sector. It has developed and commercialized a proprietary adhesive technology, MicroSkin®, which forms the core of its ostomy pouching systems designed for enhanced patient comfort and lifestyle flexibility. The company operates a direct-to-consumer e-commerce model, offers Medicare reimbursement, and targets the global ostomy care market. Its value proposition centers on a durable, waterproof, and breathable barrier that supports an active lifestyle.

Ostomy Care

Technology Platform

MicroSkin®, a proprietary transparent, hypoallergenic, latex-free polyurethane polymer film that is thin (1/1000 inch), highly elastic (500% stretch), waterproof, breathable, and durable. It serves as the adhesive barrier for all ostomy pouching systems.

Opportunities

The growing global ostomy care market, driven by aging demographics and cancer rates, presents a significant opportunity.
Cymed can capitalize on direct-to-consumer trends and leverage Medicare reimbursement to gain share by targeting active ostomates and patients with sensitive skin who are underserved by traditional products.

Risk Factors

Intense competition from large, established medical device companies with greater resources and market reach poses a major threat.
The company's dependence on a single technology platform and susceptibility to changes in U.S.
healthcare reimbursement policy are significant financial and operational risks.

Competitive Landscape

Cymed competes in the ostomy care market against dominant multinational players like Coloplast, ConvaTec, and Hollister. Its competitive advantage is its proprietary MicroSkin® adhesive, which offers superior comfort and durability for active users. However, it lacks the broad product portfolios and deep clinical relationships of its larger rivals.